154 related articles for article (PubMed ID: 32333728)
1. PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation.
Vigliar E; Iaccarino A; Campione S; Campanino MR; Clery E; Pisapia P; De Luca C; Bellevicine C; Malapelle U; De Dominicis G; Troncone G
Diagn Cytopathol; 2020 Jul; 48(7):595-603. PubMed ID: 32333728
[TBL] [Abstract][Full Text] [Related]
2. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
4. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
5. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
7. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
8. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
11. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
[TBL] [Abstract][Full Text] [Related]
12. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
[TBL] [Abstract][Full Text] [Related]
13. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
[TBL] [Abstract][Full Text] [Related]
15. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples.
KulaÇ İ; Aydin A; Bulutay P; Firat P
Turk Patoloji Derg; 2020; 36(3):205-210. PubMed ID: 32692398
[TBL] [Abstract][Full Text] [Related]
18. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
19. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
20. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
